Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-12-05
2006-12-05
Richter, Johann (Department: 0514)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S181000, C544S137000, C546S209000
Reexamination Certificate
active
07144903
ABSTRACT:
Compounds, compositions and methods are provided that are useful in the treatment of chemokine receptor-mediated conditions and diseases. In particular, the invention provides compounds which modulate CCR4 function or a CCR4-mediated response. The subject compounds and compositions are useful for the treatment or prevention of inflammatory conditions and diseases.
REFERENCES:
patent: 2863874 (1958-12-01), Gregory
patent: 3201409 (1965-08-01), Spivack et al.
patent: 3228888 (1966-01-01), Spivack et al.
patent: 3467666 (1969-09-01), Dexter et al.
patent: 3896223 (1975-07-01), Ariyan et al.
patent: 4275210 (1981-06-01), Paget, Jr.
patent: 4826990 (1989-05-01), Musser et al.
patent: 5919776 (1999-07-01), Hagmann et al.
patent: 6207665 (2001-03-01), Bauman et al.
patent: 6426360 (2002-07-01), Weier et al.
patent: 6436967 (2002-08-01), Talley et al.
patent: 6498161 (2002-12-01), Caldwell et al.
patent: 6706767 (2004-03-01), Saxena et al.
patent: 6784195 (2004-08-01), Hale et al.
patent: 2002/0173524 (2002-11-01), Collins et al.
patent: 2003/0018022 (2003-01-01), Collins et al.
patent: 2004/0039035 (2004-02-01), Collins et al.
patent: 0 310 370 (1989-04-01), None
patent: 1 050 307 (2000-11-01), None
patent: 01 98 1850 (2005-03-01), None
patent: WO 99/04794 (1999-02-01), None
patent: WO 99/38514 (1999-08-01), None
patent: WO 99/38845 (1999-08-01), None
patent: WO 99/42455 (1999-08-01), None
patent: WO 00/41724 (2000-07-01), None
patent: WO 00/42074 (2000-07-01), None
patent: WO02/030357 (2002-04-01), None
patent: WO 02/30358 (2002-04-01), None
patent: WO 02/34745 (2002-05-01), None
Das, et al., “Thiazole derivatives as possible fungicides. I, 2-(Substituted amino)-4,5-dimethylthiazoles” Chemical Abstracts 49:11626c (1955).
Fernandes, et al., “Chemotherapy of malaria. II. Synthesis of some thiazole derivatives” Chemical Abstracts 48:4513g (1954).
Mahapatra, et al., “Prepn. of N-substituted 2-aminothiazoles. III. Condensation of propyl methyl ketone with substituted thio-ureas” Chemical Abstracts 50:962h (1956).
Mahapatra, et al., “Separation of isomeric ureas and oxazoles by thin-layer chromatography” 193(2):338-339.
Nayak, et al., “Synthesis, fungicidal, antispasmodic, and antihistaminic activity of some 2-substituted thiazoles” Chemical Abstracts 114:23843 (1991).
Pascual, “Preparation of substituted 2-aminooxazole-4-carbonitriles” Helv. Chim. Acta. 72(3):556-569 (1989).
Tripathy, et al., “Paper and thin-layer chromatographic studies on the separation of mixtures of isomeric mono and diaryl thioureas, thiazoles, and thiazolines” Chemical Abstracts 80:27161 (1974).
National Institutes of Health, Web Page (http://www.csr.nih.gov/review/cvsirg.htm) referring to atherosclerosis as chronic inflammatory disease at p. 14 (Jun. 29, 2004).
Sun, et al. “Cytokine-induced enhancement of autoimmune inflammation in the brain and spinal cord: implications for multiple sclerosis” Neuropathol Appl Neurobiol. 2004 Aug.; 30(4): 374-84.
Muller, et al., “Chemokines and chemokine receptors: potential therapeutic targets in multiple sclerosis” Curr Drug Targets Inflamm. Allergy. 2004 Sep.; 3(3):279-90.
Imai, et al. “Macrophage-derived Chemokine Is a Functional Ligand for the CC Chemokine Receptor 4” J. Biol. Chem. 273:1764-1768 (1998).
Imai, et al. “The T-Cell-directed CC Chemokine TARC Is a Highly Specific Biological Ligand for CC ChemokineReceptor 4” J. Biol. Chem. 272:15036-15042 (1997).
Kita, et al. “Chemokines Active on Eosinophils: Potential Roles in Allergic Inflammation” J. Exp. Med. 183, 2421-2426 (1996).
Baggiolini “Chemokines and leukocyte traffic” Nature 392:565-8 (1998).
Baggiolini, et al. “Blocking ChemokineReceptors” J. Exp. Med. 186:1189-1191 (1997).
Collins Tassie
Houze Jonathan
Huang Alan Xi
Mahmud Hossen
Medina Julio C.
Jones Day
Richter Johann
Sackey Ebenezer
LandOfFree
CCR4 antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with CCR4 antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and CCR4 antagonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3676697